JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pham, I.
Right arrow Articles by Michel, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pham, I.
Right arrow Articles by Michel, J. B.

Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension

I Pham, W Gonzalez, AI el Amrani, MC Fournie-Zaluski, M Philippe, I Laboulandine, BP Roques and JB Michel

Institut National de la Sante et de la Recherche Medicale U 637, Paris, France.

Angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) are implicated in the metabolism of several peptides involved in blood pressure and sodium homeostasis control, such as angiotensins, atrial natriuretic factor (ANF), bradykinin and endothelin. The effects of a highly selective NEP inhibitor (NEPI), retrothiorphan, of a converting enzyme inhibitor (CEI), enalaprilat, and of the combination, CEI + NEPI, were assessed in deoxycorticosterone acetate (DOCA)-salt hypertensive rats, spontaneously hypertensive rats (SHRs) and renovascular hypertensive rats. NEPI increased diuresis, natriuresis and urinary cyclic GMP (cGMP), ANF and bradykinin in the three models. NEPI decreased blood pressure in DOCA-salt hypertensive rats only, whereas CEI decreased blood pressure in SHRs and renovascular hypertensive rats only and increased plasma renin. CEI had no effect on urinary aldosterone or bradykinin in any of the three models. CEI + NEPI increased diuresis and natriuresis in DOCA-salt hypertensive rats and SHRs, and increased urinary cGMP, ANF and bradykinin and plasma renin levels. CEI and NEPI interacted significantly to decrease blood pressure and to increase urinary cGMP in SHRs only. Hence, NEPI increases diuresis, natriuresis and urinary cGMP, ANF and bradykinin in experimental hypertension, whereas CEI acts on blood pressure and increases in plasma renin in SHRs and renovascular hypertensive rats. The significant interaction between CEI and NEPI to decrease blood pressure in SHRs indicates that simultaneous blockade of the two metallopeptidases results in potentiation of the hypotensive effect and that the SHRs appear to be a good model for studying NEP and ACE coinhibition. Finally, NEP rather than ACE appears to be involved in bradykinin renal catabolism in experimental hypertension.

Volume 265, Issue 3, pp. 1339-1347, 06/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Vet PatholHome page
Y. Takeuchi, K. Uetsuka, M. Murayama, F. Kikuta, A. Takashima, K. Doi, and H. Nakayama
Complementary Distributions of Amyloid-{beta} and Neprilysin in the Brains of Dogs and Cats
Vet. Pathol., July 1, 2008; 45(4): 455 - 466.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. M. Gardiner, J. E. March, P. A. Kemp, S. A. Ballard, and T. Bennett
Regional Hemodynamic Effects of Neutral Endopeptidase Inhibition and Angiotensin (AT1) Receptor Antagonism Alone or in Combination in Conscious Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 340 - 348.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
S. I. McFarlane, N. Winer, and J. R. Sowers
Role of the Natriuretic Peptide System in Cardiorenal Protection
Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. S. Mozaffari and S. W. Schaffer
Effect of Hypertension and Hypertension-Glucose Intolerance on Myocardial Ischemic Injury
Hypertension, November 1, 2003; 42(5): 1042 - 1049.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. J. Campbell
Vasopeptidase Inhibition: A Double-Edged Sword?
Hypertension, March 1, 2003; 41(3): 383 - 389.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
G. A Sagnella
Review: Vasopeptidase inhibitors
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 90 - 95.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
F. Ruschitzka, R. Corti, T. Quaschning, M. Hermann, and T. F. Luscher
Vasopeptidase inhibitors--concepts and evidence
Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1532 - 1535.
[Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
G. A Sagnella
Practical implications of current natriuretic peptide research
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 304 - 315.
[PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. BAILLY
Effect of Luminal Atrial Natriuretic Peptide on Chloride Reabsorption in Mouse Cortical Thick Ascending Limb: Inhibition by Endothelin
J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1791 - 1797.
[Abstract] [Full Text]


Home page
HypertensionHome page
H. D. Intengan and E. L. Schiffrin
Vasopeptidase Inhibition Has Potent Effects on Blood Pressure and Resistance Arteries in Stroke-Prone Spontaneously Hypertensive Rats
Hypertension, June 1, 2000; 35(6): 1221 - 1225.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Laurent, P. Boutouyrie, M. Azizi, C. Marie, C. Gros, J.-C. Schwartz, J.-M. Lecomte, and J. Bralet
Antihypertensive Effects of Fasidotril, a Dual Inhibitor of Neprilysin and Angiotensin-Converting Enzyme, in Rats and Humans
Hypertension, May 1, 2000; 35(5): 1148 - 1153.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A.-M. Duncan, G. M. James, F. Anastasopoulos, A. Kladis, T. A. Briscoe, and D. J. Campbell
Interaction Between Neutral Endopeptidase and Angiotensin Converting Enzyme Inhibition in Rats with Myocardial Infarction: Effects on Cardiac Hypertrophy and Angiotensin and Bradykinin Peptide Levels
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 295 - 303.
[Abstract] [Full Text]


Home page
Protein Eng Des SelHome page
G. Tiraboschi, N. Jullian, V. Thery, S. Antonczak, M.-C. Fournie-Zaluski, and B. P. Roques
A three-dimensional construction of the active site (region 507–749) of human neutral endopeptidase (EC.3.4.24.11)
Protein Eng. Des. Sel., February 1, 1999; 12(2): 141 - 149.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Tikkanen, I. Tikkanen, M. D. Rockell, T. J. Allen, C. I. Johnston, M. E. Cooper, and L. M. Burrell
Dual Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme in Rats With Hypertension and Diabetes Mellitus
Hypertension, October 1, 1998; 32(4): 778 - 785.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. L. Thomas, J. E. Artwohl, H. Suzuki, X.-p. Gao, E. White, A. Saroli, R. M. Bunte, and I. Rubinstein
Initial Characterization of Hamsters With Spontaneous Hypertension
Hypertension, August 1, 1997; 30(2): 301 - 304.
[Abstract] [Full Text]


Home page
HypertensionHome page
J. G. Motwani, C. C. Lang, G. Cramb, and A. D. Struthers
Natriuretic Response to Neutral Endopeptidase Inhibition Is Blunted by Enalapril in Healthy Men
Hypertension, April 1, 1995; 25(4): 637 - 642.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics.